# Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

> **NCT06194656** · PHASE2 · RECRUITING · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 81 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** HER3 Monoclonal antibodies-Dose A
- **DRUG:** HER3 Monoclonal antibodies-Dose B
- **DRUG:** HER3 Monoclonal antibodies-Dose C
- **OTHER:** HER3 Monoclonal antibodies-Dose D
- **OTHER:** Placebo
- **COMBINATION_PRODUCT:** Cetuximab injection

## Key facts

- **NCT ID:** NCT06194656
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-27
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06194656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06194656, "Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06194656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*